Four Directors at Deutsche Pfandbriefbank AG bought 32,013 shares at between 5.410EUR and 5.559EUR. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...
The Q2/25 KPIs show a deterioration in revenue and EBITDA margins - contrary to management and market expectations (revenue -6% YoY to €171.2m / margin: -4.08%; EPS €-0.25), but these are exaggerated due to phasing effects and reset savings. Revenue and margins in the "restart phase" starting Q3/25 are expected to expand. However, the necessary revival of customer demand in the pharma and biotech industry is still lacking (contractionary US R&D and industrial policy, hesitant investments). There...
Die Q2/25-KPIs zeigen - entgegen der Management- und Markt-Erwartung - eine Umsatz- und EBITDA Margen-Verschlechterung (Umsatz -6% YoY auf € 171,2 Mio./Marge: -4,08 %; EPS € -0,25), doch sind diese durch Phasing-Effekte und Reset-Einsparungen überzeichnet. Umsatz und Margen in der „Restart-Phase“ ab Q3/25 sollen ausgeweitet werden. Doch die dafür nötige wiederauflebende Kundennachfrage in Pharma- und Biotech-Industrie bleibt bis heute aus (kontraktive US-R&D- und Industriepolitik, zögerliche Inv...
Following yesterday's cut to sales guidance, we cut our PT to €5.40 and L-T revenues by 10-15%. We are 40% below consensus EBITDA in 2028 despite including significantly more cost savings. We show the base business is loss making this year & could just break even in 2026. We are most concerned about the reliance on single lumpy contracts. The SDZ milestones will mostly disappear by 2028 & the commercial revenues required to offset them imply biosimilar sales of €550m by 2030 for drugs that will ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.